Company profile
Shenyang Sunshine Pharmaceutical
Privately held: no public share price
Assets
(4 total)
4Total Assets
0Approved
2Phase 3 / Filed
2Phase 1–2 / Early
2Diseases
Quick filter:
| Target & Modality | |||
|---|---|---|---|
| Phase 3 | PD-1 + VEGFMultispecific antibody | Non-Small Cell Lung Cancer | |
| Phase 3 | Erythropoietin receptor (EPO-R)Biologic (subtype unspecified) | Chronic Kidney Disease | |
| Phase 2 | PD-1 and PD-L1Multispecific antibody | Non-Small Cell Lung Cancer | |
| Phase 2 | HIF prolyl hydroxylase (HIF-PH1/2/3)Small molecule | Chronic Kidney Disease |
Upcoming events
Research
Unlock the company readout calendar
Research includes estimated primary-completion dates, earnings report dates, and 'What to watch' trial analysis across this company’s pipeline.
Financial reports
Research
Unlock sourced financial history
Research includes quarterly, interim and annual revenue, R&D, cash and burn figures linked to the underlying company reports.